The Weekly Recap 10/17/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

 In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, announce strategic partnerships, achieve clinical milestones, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).

Adagio Medical

Announced that it entered into a securities purchase agreement worth up to $50M in proceeds, with the agreement expected to result in ~$19M in upfront proceeds. The company plans to use the funds for working capital and general corporate purposes, including the advancement of its clinical and product development activities.

Avisi Technologies

Announced that the FDA has approved an IDE submission for its VisiPlateⓇ for glaucoma treatment. The SAPPHIRE trial is a prospective, multicenter, open-label clinical trial with one-year follow-up that will evaluate the safety and effectiveness of its VisiPlate aqueous shunt.

Berlin Heals

Completed enrollment in the first-in-human Phase I CMIC-III study evaluating a less invasive approach to implanting its C-MIC device. The study supports Berlin Heals’ plans to expand the new, less invasive approach to a wider population of patients and advance toward a pivotal FDA IDE trial.

CAPS Medical

Announced that its PlasmaSure™ System received Breakthrough Device Designation from the FDA for treating low- to intermediate-risk non-muscle invasive bladder cancer (NMIBC). The designation supports CAPS Medical’s mission to replace traditional TURBT, hospitalization, and general anesthesia with a simple office-based tumor ablation.

DASI Simulations

Announced a two-year co-development partnership with Cleveland Clinic to create the world’s first AI-powered “co-pilot” system for catheterization labs. Cleveland Clinic will also use DASI Simulations’ existing technology to support planning and treatment for current TAVR patients at Cleveland Clinic.

Field Medical

Announced that Circulation has published six-month outcomes from VCAS, the first-in-human trial of its FieldForce™ Ablation System, showing 82% freedom from recurrent VT/VF or ICD therapy and a 98% reduction in VT/VF burden. The results support the system’s potential to treat scar-related VT and advance Field’s FDA Breakthrough-designated program toward a pivotal trial.

Innitius

Received authorization from the Spanish Agency of Medicines and Medical Devices to initiate the pivotal international phase of its FB-CT2 study evaluating CerviSenseⓇ TPTL, a diagnostic tool for predicting spontaneous preterm birth. The study will enroll 357 patients across Spain and Germany to confirm device performance in real-world clinical practice.

LightHearted AI

Was awarded AI in Health feasibility funding from Innovate UK’s Biomedical Catalyst to validate the economic case for its scalable precision cardiology platform. The project supports LightHearted AI’s mission to revolutionize heart disease diagnosis through laser-based technology and advanced AI.

This blog is originally published here: https://www.lifesciencemarketresearch.com/insights/the-weekly-recap-101725-lsi-alumni-achievements-driving-medtech-and-healthtech-forward

Comments

Post a Comment

Popular posts from this blog

Cover Story: A Page from Ray Cohen’s Playbook: Scaling, Exiting, and Winning in Medtech

With four decades of company-building, IPOs, boardroom leadership, and monumental exits behind him, Raymond W. Cohen has become one of medtech’s most successful operators. But behind the financial wins — including the recent back-to-back $3.7 billion Axonics and $600 million SoniVie acquisitions by Boston Scientific — is a deeper story of Cohen’s contrarian, full-transparency, people-centered, no-BS approach to leadership and strategy. “People crave inspired, authentic, and transparent leadership that thinks big and acts boldly. They want to be enrolled in a vision of what is possible, and be recognized and compensated for creating measurable results, not be fed a bunch of platitudes.” A quote that is classic  Ray Cohen  — blunt, unapologetic, no-nonsense, and grounded in hard-won experience. With more than four decades in medtech, Cohen has done what many aspire to — build, lead, scale, and sell high-stakes, successful ventures with precision and zero fluff. Known for his no-...
Read more

The Weekly Recap 6/13/25: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure over $63M in new funds, receive FDA 510(k) clearances, announce an acquisition, and much more as we wind down   LSI Asia  ’25 in Singapore and gear up for  LSI Europe  ’25 in London (September 7–11). Accelus Received FDA 510(k) clearance for the FlareHawk Interbody Fusion System to be safely subjected to MRI scanning in certain conditions. The clearance supports Accelus’s commitment to safe, high-performance spinal solutions and expands imaging options for patients with FlareHawk implants. Aortyx Raised $16M to advance its bioresorbable aortic patch toward first-in-human trials. The funding supports continued development of Aortyx’s minimally invasive, tissue-regenerating solution for aortic dissection and positions the company for clinical entry within two years. Atraverse Medical Closed $29.4M in follow-on financing to scale U.S. commercialization of HOTW...
Read more

Medtech in 2025: Key Insights from Q1 Earnings

  As we venture into Q2 of 2025, the medtech industry continues to navigate challenges while remaining on a positive growth trajectory. The early earnings reports from major medtech companies provide valuable insights into how the sector is performing and where it is heading. Despite the pressures of ongoing macroeconomic uncertainty, the first quarter of 2025 shows a sector that’s resilient, with many companies reporting strong growth across their key divisions. For more information visit here:  https://www.slideshare.net/slideshow/medtech-in-2025-key-insights-from-q1-earnings/279045324
Read more